BioCardia Submits Revised FDA Pre-Submission for Helix Catheter Approval
BioCardia filed a revised pre-submission with the FDA's CDRH seeking De Novo approval for its Helix Catheter cardiac delivery device.
BioCardia, Inc. (Nasdaq: BCDA) announced Thursday it has completed a revised pre-submission to the U.S. Food and Drug Administration's Center for Devices and Radiological Health under the agency's Q-Submission program, moving the Sunnyvale, California-based company a step closer to potential clearance of its Helix Catheter.
The submission targets De Novo classification, a regulatory pathway the FDA uses for novel, low-to-moderate-risk medical devices that lack a legally marketed predicate. The Helix Catheter is designed to deliver therapeutic and diagnostic agents directly to the heart, a function central to BioCardia's broader focus on cellular and cell-derived treatments for cardiovascular and pulmonary diseases.
Read more Sigo Seguros Opens Auto Insurance MCP Server to AI Chatbots →
The Q-Submission program allows device makers to engage with FDA reviewers before a formal application, giving companies an opportunity to resolve potential deficiencies early and improve the odds of a successful review. BioCardia's decision to file a revised pre-submission suggests the company has addressed prior agency feedback as it works toward a full De Novo application.
BioCardia positions itself as a global leader in cellular therapeutics for heart and lung conditions. Regulatory clearance of the Helix Catheter would expand the company's commercial toolkit and could support ongoing and future clinical programs that rely on precise intracardiac agent delivery.
Continue reading at GlobeNewswire - Industry News on Financial Services.
